Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE
Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.
The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 20.78%. Akorn's revenue for the same period is $304.28 million.
The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP) is 17.90%. Salix Pharma's operating margin for the same period is 26.47%.
The trailing-twelve-month return on equity at Mylan (NASDAQ: MYL) is 17.73%. Mylan's EPS for the same period is $1.52.
The trailing-twelve-month return on equity at Sagent Pharmaceuticals (NASDAQ: SGNT) is 16.09%. Sagent Pharma's profit margin for the same period is 12.09%.
Posted-In: Drugs-Generic Industry NASDAQ ROETrading Ideas
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
